GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evofem Biosciences Inc (OTCPK:EVFM) » Definitions » Cyclically Adjusted PS Ratio

Evofem Biosciences (Evofem Biosciences) Cyclically Adjusted PS Ratio : 0.00 (As of May. 28, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Evofem Biosciences Cyclically Adjusted PS Ratio?

As of today (2024-05-28), Evofem Biosciences's current share price is $0.0159. Evofem Biosciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $62.34. Evofem Biosciences's Cyclically Adjusted PS Ratio for today is 0.00.

The historical rank and industry rank for Evofem Biosciences's Cyclically Adjusted PS Ratio or its related term are showing as below:

During the past years, Evofem Biosciences's highest Cyclically Adjusted PS Ratio was 0.04. The lowest was 0.01. And the median was 0.01.

EVFM's Cyclically Adjusted PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 5.5
* Ranked among companies with meaningful Cyclically Adjusted PS Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Evofem Biosciences's adjusted revenue per share data for the three months ended in Mar. 2024 was $0.116. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $62.34 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Evofem Biosciences Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Evofem Biosciences's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evofem Biosciences Cyclically Adjusted PS Ratio Chart

Evofem Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Evofem Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.01 - - -

Competitive Comparison of Evofem Biosciences's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Evofem Biosciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evofem Biosciences's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evofem Biosciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Evofem Biosciences's Cyclically Adjusted PS Ratio falls into.



Evofem Biosciences Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Evofem Biosciences's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=0.0159/62.34
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evofem Biosciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Evofem Biosciences's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.116/131.7762*131.7762
=0.116

Current CPI (Mar. 2024) = 131.7762.

Evofem Biosciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 0.000 99.792 0.000
201603 0.000 100.470 0.000
201606 0.000 101.688 0.000
201609 0.000 101.861 0.000
201612 0.000 101.863 0.000
201703 0.000 102.862 0.000
201706 0.000 103.349 0.000
201709 0.000 104.136 0.000
201712 0.000 104.011 0.000
201803 0.000 105.290 0.000
201806 0.000 106.317 0.000
201809 0.000 106.507 0.000
201812 0.000 105.998 0.000
201903 0.000 107.251 0.000
201906 0.000 108.070 0.000
201909 0.000 108.329 0.000
201912 0.000 108.420 0.000
202003 0.000 108.902 0.000
202006 0.000 108.767 0.000
202009 6.465 109.815 7.758
202012 3.907 109.897 4.685
202103 25.114 111.754 29.613
202106 27.716 114.631 31.861
202109 20.878 115.734 23.772
202112 41.512 117.630 46.504
202203 47.764 121.301 51.889
202206 27.806 125.017 29.309
202209 1.434 125.227 1.509
202212 0.184 125.222 0.194
202303 4.567 127.348 4.726
202306 1.560 128.729 1.597
202309 0.007 129.860 0.007
202312 0.242 129.419 0.246
202403 0.116 131.776 0.116

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Evofem Biosciences  (OTCPK:EVFM) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Evofem Biosciences Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Evofem Biosciences's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Evofem Biosciences (Evofem Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
7770 Regents Road, Suite 113-618, San Diego, CA, USA, 92122
Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.
Executives
Yan Zhang officer: Chief Financial Officer 6166 TIKI CT, SAN DIEGO CA 92130
Kim P. Kamdar director, 10 percent owner C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Jenny C. Yip director 12400 HIGH BLUFF DR., STE. 600, SAN DIEGO CA 92130
Atkinson Katherine Cocca officer: Chief Commercial Officer 12400 HIGH BLUFF., STE. 600, SAN DIEGO CA 92130
Saundra L Pelletier director, officer: Chief Executive Officer C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Alexander A Fitzpatrick officer: General Counsel and Secretary 9605 SCRANTON ROAD, SUITE 200, SAN DIEGO CA 92121
Justin J. File officer: Chief Financial Officer C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Anthony Stephen O'brien director C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Russell Barrans officer: Chief Commercial Officer C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Lisa Dale Rarick director C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, STE 600, SAN DIEGO CA 92130
William Walmsley Hall director C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DIRVE, SUITE 600, SAN DIEGO CA 92130
Invesco Ltd. 10 percent owner 1331 SPRING STREET NW, SUITE 2500, ATLANTA GA 30309
Link Fund Solutions Ltd 10 percent owner 65 GRESHAM STREET, LONDON X0 EC2V 7NQ
Acacia Research Corp 10 percent owner 767 3RD AVENUE, 6TH FLOOR, NEW YORK NY 10017
Kelly Culwell officer: Chief Medical Officer C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130